[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]. - Shelan M; Mathier E; Aebersold DM; Wiegel T (Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025)